DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
« Back to Dashboard
Tazemetostat hydrobromideis the generic ingredient in one branded drug marketed by Epizyme Inc and is included in one NDA. There are twenty-three patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Tazemetostat hydrobromide has three hundred and one patent family members in thirty-eight countries.
Recent Clinical Trials for tazemetostat hydrobromide
Identify potential brand extensions & 505(b)(2) entrants
|National Cancer Institute (NCI)||Phase 1/Phase 2|
|Country||Patent Number||Estimated Expiration|
|South Korea||102154946||⤷ Free Forever Trial|
|Spain||2706951||⤷ Free Forever Trial|
|Australia||2013232229||⤷ Free Forever Trial|
|Japan||6829684||⤷ Free Forever Trial|
|Israel||261964||⤷ Free Forever Trial|
|>Country||>Patent Number||>Estimated Expiration|